ITU Tier 1+ #32: Pharmaceuticals (K_pharma)
Munehiro Terada · Zenodo (CERN European Organization for Nuclear Research) · 2026
Tier 1+ Pass-1.5 paper 32 of 45. ITU-derived pharmaceuticals on target + chem + PK + efficacy + safety. Drug pipeline funnel + GLP-1 + AI drug discovery. Defines K_pharma = -log ρ_pharma as the operator-algebraic modular Hamiltonian on H_target ⊗ H_chemistry ⊗ H_PK ⊗ H_efficacy ⊗ H_safety. K_pharma inherits from K_QG via the CLPW 2023 type II crossed-product specialised to this scale. Numerical results. GLP-1 Semaglutide STEP Wegovy + Tirzepatide SURMOUNT 2024 $58B; Cobenfy KarXT BMS 2024.9.27; Lecanemab + Donanemab 2023/2024; Casgevy CRISPR 2023.12.8; AI-discovered Insilico Phase 2a 2024. Topics covered. BIO 2024 pipeline 5.21% success, GLP-1 $58B Wegovy/Zepbound, Cobenfy 2024.9.27 first non-D2 antipsychotic 70yr, Lecanemab/Donanemab 2023.1.6/2024.7.2, Casgevy/Lyfgenia 2023.12.8 first CRISPR, AI-discovered drug Insilico 2024, Loyal LOY-002 2024.11.26 first lifespan drug, MDMA-AT Lykos REJECTED 2024.8.9, IRA 2022.8 + first 10 negotiated drugs 2024.8.15 effective 2026. 45-vertex polytope #32 top couplings: #5 Cancer (0.95), #7 Psych (0.95), #27 Microbe (0.92), #30 K_genome (0.92), #6 Aging (0.92), #26 Chiral (0.92). Ten falsifiable predictions: P_avg=0.66: arXiv 2026 (0.90 S), GLP-1 Alzheimer Phase 3 2027 (0.65 M), AI drug approvals 5+ by 2028 (0.55 M). Pass-2 roadmap: ~$1.7M: Pharma analytics ($600K) + Lean Mathlib ($200K) + AI drug + clinical collab ($900K). Copyright © 2026 Munehiro Terada / Roboken. Licensed under CC-BY-4.0.